Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $20 | $21 | $26 | $18 |
| % Growth | -6.6% | -21.1% | 43.5% | – |
| Cost of Goods Sold | $3 | $3 | $8 | $2 |
| Gross Profit | $17 | $18 | $19 | $16 |
| % Margin | 86.4% | 85.6% | 70.4% | 87.8% |
| R&D Expenses | $11 | $11 | $12 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11 | $13 | $12 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $24 | $25 | $25 |
| Operating Income | -$6 | -$7 | -$6 | -$9 |
| % Margin | -28.7% | -31.3% | -22.4% | -46.4% |
| Other Income/Exp. Net | $2 | $1 | -$2 | $2 |
| Pre-Tax Income | -$3 | -$5 | -$8 | -$7 |
| Tax Expense | $0 | $0 | -$1 | $0 |
| Net Income | -$3 | -$5 | -$7 | -$7 |
| % Margin | -16.6% | -24.9% | -25.6% | -37.9% |
| EPS | -0.072 | -0.12 | -0.15 | -0.16 |
| % Growth | 40.4% | 20% | 6.3% | – |
| EPS Diluted | -0.072 | -0.12 | -0.15 | -0.16 |
| Weighted Avg Shares Out | 45 | 45 | 45 | 45 |
| Weighted Avg Shares Out Dil | 45 | 45 | 45 | 45 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | -$2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$5 | -$6 | -$8 |
| % Margin | -28.7% | -24.5% | -22% | -45.8% |